Gilder Gagnon Howe & CO LLC Stoke Therapeutics, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

$8.56 Billion
Q4 2024

A detailed history of Gilder Gagnon Howe & CO LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 92,546 shares of STOK stock, worth $701,498. This represents 0.01% of its overall portfolio holdings.

Number of Shares

92,546

Previous 90,755 1.97%

Holding current value

$701,498

Previous $1.12 Million 8.52%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$10.8 - $13.92 $19,342 - $24,930	1,791 Added 1.97%	92,546 $1.02 Million
Q3 2024 Nov 14, 2024	BUY	$12.24 - $15.92 $26,658 - $34,673	2,178 Added 2.46%	90,755 $1.12 Million
Q2 2024 Aug 14, 2024	SELL	$11.03 - $17.52 $13,302 - $21,129	-1,206 Reduced 1.34%	88,577 $1.2 Million
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $113,444 - $390,170	27,535 Added 44.23%	89,783 $1.21 Million
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $37 - $59	-11 Reduced 0.02%	62,248 $327,000
Q3 2023 Nov 14, 2023	BUY	$3.78 - $11.99 $42,279 - $134,108	11,185 Added 21.9%	62,259 $245,000
Q2 2023 Aug 14, 2023	SELL	$7.93 - $13.82 $6,843 - $11,926	-863 Reduced 1.66%	51,074 $542,000
Q1 2023 May 15, 2023	BUY	$7.65 - $10.38 $224,397 - $304,476	29,333 Added 129.77%	51,937 $432,000
Q4 2022 Feb 14, 2023	SELL	$7.07 - $15.69 $249,288 - $553,229	-35,260 Reduced 60.94%	22,604 $208,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $22.53 $5,589 - $10,025	-445 Reduced 0.76%	57,864 $743,000
Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $5.24 Million - $12.1 Million	-506,207 Reduced 89.67%	58,309 $770,000
Q1 2022 May 16, 2022	SELL	$17.19 - $26.1 $8.73 Million - $13.3 Million	-507,924 Reduced 47.36%	564,516 $11.9 Million
Q4 2021 Feb 14, 2022	SELL	$18.11 - $30.72 $922,070 - $1.56 Million	-50,915 Reduced 4.53%	1,072,440 $25.7 Million
Q3 2021 Nov 15, 2021	SELL	$23.65 - $34.44 $2.9 Million - $4.22 Million	-122,601 Reduced 9.84%	1,123,355 $28.6 Million
Q2 2021 Aug 16, 2021	SELL	$30.53 - $41.09 $610,416 - $821,553	-19,994 Reduced 1.58%	1,245,956 $41.9 Million
Q1 2021 May 17, 2021	SELL	$36.08 - $69.81 $7.39 Million - $14.3 Million	-204,891 Reduced 13.93%	1,265,950 $49.2 Million
Q4 2020 Feb 16, 2021	SELL	$33.62 - $61.93 $649,269 - $1.2 Million	-19,312 Reduced 1.3%	1,470,841 $91.1 Million
Q3 2020 Nov 16, 2020	SELL	$22.23 - $37.48 $1.77 Million - $2.98 Million	-79,411 Reduced 5.06%	1,490,153 $49.9 Million
Q2 2020 Aug 14, 2020	SELL	$20.26 - $29.73 $2.37 Million - $3.48 Million	-117,183 Reduced 6.95%	1,569,564 $37.4 Million
Q1 2020 May 15, 2020	SELL	$16.8 - $34.15 $2.35 Million - $4.79 Million	-140,143 Reduced 7.67%	1,686,747 $38.6 Million
Q4 2019 Feb 14, 2020	SELL	$20.01 - $30.79 $986,513 - $1.52 Million	-49,301 Reduced 2.63%	1,826,890 $51.7 Million
Q3 2019 Nov 14, 2019	BUY	$20.53 - $37.72 $299,081 - $549,504	14,568 Added 0.78%	1,876,191 $40.3 Million
Q2 2019 Aug 13, 2019	BUY	$25.53 - $29.17 $47.5 Million - $54.3 Million	1,861,623 New	1,861,623 $54.3 Million

Others Institutions Holding STOK

# of Institutions

136

Shares Held

57.3M

Call Options Held

5.7K

Put Options Held

24.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $299M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.

Account

Gilder Gagnon Howe & CO LLC Stoke Therapeutics, Inc. Transaction History